Essa Pharma reports Q4 EPS (14c), consensus (27c)

As of September 30, the company had available cash reserves and short-term investments of $126.8M and net working capital of $124.3M. The Company has no long-term debt facilities. “We recently made the difficult decision to terminate the clinical development of masofaniten, and withdraw the related IND and CTAs, based on an interim analysis of the data from the Phase 2 combination study, concluding that masofaniten combined with enzalutamide was unlikely to meet its primary endpoint,” said David Parkinson, CEO. “We are currently evaluating and reviewing our strategic options focused on maximizing shareholder value and look forward to providing further updates in the near future.”